See more : AptaBio Therapeutics Inc. (293780.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Ipca Laboratories Limited (IPCALAB.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ipca Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Kansai Food Market Ltd. (9919.T) Income Statement Analysis – Financial Results
- Anhui Sinonet & Xinlong Science & Technology Co., Ltd. (002298.SZ) Income Statement Analysis – Financial Results
- Huafon Microfibre (Shanghai) Co., Ltd. (300180.SZ) Income Statement Analysis – Financial Results
- China Everbright Environment Group Limited (CHFFY) Income Statement Analysis – Financial Results
- Allied Farmers Limited (ALF.NZ) Income Statement Analysis – Financial Results
Ipca Laboratories Limited (IPCALAB.BO)
About Ipca Laboratories Limited
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 76.22B | 62.07B | 57.66B | 53.66B | 45.59B | 36.92B | 32.07B | 30.93B | 28.68B | 31.17B | 32.47B | 27.81B | 23.31B | 19.00B | 15.60B | 12.84B | 10.51B | 9.28B | 7.60B | 6.79B |
Cost of Revenue | 46.41B | 24.08B | 21.06B | 18.02B | 17.09B | 12.90B | 11.76B | 11.64B | 11.11B | 12.10B | 11.85B | 11.46B | 9.54B | 7.76B | 6.46B | 5.07B | 4.64B | 4.01B | 3.49B | 4.74B |
Gross Profit | 29.81B | 37.99B | 36.60B | 35.64B | 28.50B | 24.02B | 20.30B | 19.29B | 17.57B | 19.07B | 20.62B | 16.35B | 13.77B | 11.23B | 9.14B | 7.77B | 5.87B | 5.27B | 4.10B | 2.05B |
Gross Profit Ratio | 39.11% | 61.21% | 63.48% | 66.42% | 62.51% | 65.05% | 63.32% | 62.37% | 61.27% | 61.18% | 63.51% | 58.80% | 59.07% | 59.13% | 58.60% | 60.49% | 55.88% | 56.77% | 53.99% | 30.14% |
Research & Development | 718.30M | 461.30M | 417.90M | 523.80M | 313.80M | 207.40M | 266.20M | 416.80M | 404.60M | 402.60M | 624.70M | 355.40M | 252.50M | 412.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 1.17B | 761.90M | 736.50M | 970.70M | 585.80M | 799.40M | 808.10M | 578.40M | 485.50M | 485.50M | 391.50M | 350.20M | 299.60M | 2.05B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 7.09B | 5.56B | 3.70B | 2.99B | 3.32B | 2.94B | 2.53B | 2.60B | 2.14B | 2.45B | 2.31B | 2.13B | 1.96B | 1.70B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 22.25B | 6.32B | 4.43B | 3.96B | 3.90B | 3.74B | 3.33B | 3.18B | 2.62B | 2.94B | 2.70B | 2.48B | 2.26B | 3.75B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Expenses | 1.25B | 152.50M | 155.70M | 144.80M | 201.90M | 210.70M | 191.50M | 24.20M | 23.60M | 28.40M | 36.00M | 23.30M | 13.40M | -1.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 13.91B | 30.95B | 25.98B | 22.46B | 21.05B | 18.67B | 17.47B | 16.62B | 15.82B | 15.37B | 13.46B | 10.93B | 9.24B | 8.00B | 6.12B | 6.26B | 3.92B | 3.50B | 3.22B | 1.04B |
Cost & Expenses | 68.15B | 55.02B | 47.04B | 40.48B | 38.14B | 31.57B | 29.23B | 28.26B | 26.93B | 27.46B | 25.31B | 22.39B | 18.78B | 15.77B | 12.57B | 11.34B | 8.56B | 7.51B | 6.71B | 5.78B |
Interest Income | 629.30M | 793.50M | 341.70M | 369.50M | 323.00M | 274.50M | 151.30M | 127.20M | 127.10M | 188.50M | 133.90M | 85.40M | 71.30M | 59.10M | -55.40M | -5.80M | -17.80M | -15.60M | 16.17M | 11.75M |
Interest Expense | 1.38B | 450.90M | 72.40M | 86.10M | 158.40M | 183.00M | 234.30M | 210.70M | 251.10M | 234.60M | 216.10M | 275.00M | 360.80M | 294.00M | 273.90M | 312.20M | 186.10M | 209.10M | 132.60M | 83.99M |
Depreciation & Amortization | 3.57B | 2.62B | 2.32B | 2.09B | 2.11B | 1.82B | 1.78B | 1.73B | 1.63B | 1.80B | 1.03B | 867.30M | 671.30M | 557.90M | 467.40M | 396.60M | 325.10M | 294.50M | 248.50M | 192.24M |
EBITDA | 13.30B | 10.53B | 13.78B | 16.09B | 9.77B | 7.49B | 4.95B | 4.61B | 3.14B | 5.73B | 7.63B | 5.77B | 4.76B | 4.20B | 3.52B | 1.90B | 2.28B | 2.06B | 1.13B | 1.22B |
EBITDA Ratio | 17.45% | 16.54% | 23.79% | 30.12% | 21.52% | 20.09% | 15.21% | 14.75% | 10.57% | 18.19% | 23.26% | 20.45% | 20.13% | 20.31% | 22.56% | 14.79% | 21.70% | 22.22% | 14.83% | 17.88% |
Operating Income | 7.98B | 7.31B | 10.50B | 13.09B | 7.07B | 5.06B | 2.59B | 2.24B | 1.59B | 3.87B | 6.52B | 4.82B | 4.02B | 3.30B | 3.05B | 1.50B | 1.96B | 1.77B | 877.60M | 1.02B |
Operating Income Ratio | 10.47% | 11.78% | 18.21% | 24.39% | 15.51% | 13.70% | 8.07% | 7.23% | 5.56% | 12.43% | 20.08% | 17.33% | 17.25% | 17.37% | 19.56% | 11.70% | 18.61% | 19.04% | 11.55% | 15.05% |
Total Other Income/Expenses | 446.10M | -15.20B | -11.54B | -9.64B | -57.80M | 114.00M | 69.40M | -50.80M | -588.90M | -90.90M | -853.60M | -278.50M | -377.50M | 174.20M | -358.70M | -318.50M | -203.90M | -224.70M | -138.70M | -64.81M |
Income Before Tax | 8.43B | 7.45B | 11.36B | 13.89B | 7.39B | 5.46B | 2.91B | 2.62B | 1.17B | 3.61B | 6.31B | 4.54B | 3.64B | 3.41B | 2.66B | 1.18B | 1.75B | 1.54B | 745.00M | 941.13M |
Income Before Tax Ratio | 11.06% | 12.01% | 19.70% | 25.88% | 16.21% | 14.80% | 9.06% | 8.47% | 4.07% | 11.59% | 19.42% | 16.33% | 15.63% | 17.93% | 17.07% | 9.22% | 16.67% | 16.62% | 9.81% | 13.86% |
Income Tax Expense | 3.13B | 2.53B | 2.25B | 2.40B | 1.35B | 1.04B | 511.10M | 675.20M | 204.40M | 1.02B | 1.52B | 1.30B | 881.10M | 783.80M | 627.20M | 232.50M | 357.90M | 293.80M | 144.80M | 238.26M |
Net Income | 5.47B | 4.71B | 8.84B | 11.40B | 6.06B | 4.45B | 2.39B | 1.95B | 962.00M | 2.59B | 4.78B | 3.24B | 2.76B | 2.63B | 2.05B | 1.01B | 1.36B | 1.26B | 615.00M | 740.85M |
Net Income Ratio | 7.18% | 7.59% | 15.33% | 21.25% | 13.30% | 12.05% | 7.47% | 6.29% | 3.35% | 8.32% | 14.73% | 11.66% | 11.85% | 13.83% | 13.17% | 7.85% | 12.93% | 13.59% | 8.10% | 10.91% |
EPS | 21.57 | 18.58 | 34.85 | 22.51 | 23.99 | 17.61 | 9.49 | 7.71 | 3.69 | 10.07 | 18.96 | 12.83 | 10.99 | 10.48 | 8.22 | 4.01 | 5.43 | 5.05 | 2.46 | 2.96 |
EPS Diluted | 21.57 | 18.58 | 34.85 | 22.51 | 23.98 | 17.61 | 9.49 | 7.71 | 3.69 | 10.07 | 18.96 | 12.83 | 10.99 | 10.48 | 8.21 | 4.00 | 5.41 | 5.03 | 2.46 | 2.96 |
Weighted Avg Shares Out | 253.70M | 253.70M | 253.70M | 506.56M | 252.70M | 252.65M | 252.40M | 252.40M | 252.40M | 252.40M | 252.40M | 252.32M | 252.11M | 250.81M | 249.79M | 251.07M | 250.31M | 250.00M | 250.00M | 250.00M |
Weighted Avg Shares Out (Dil) | 253.70M | 253.70M | 253.70M | 506.56M | 252.88M | 252.65M | 252.42M | 252.40M | 252.40M | 252.40M | 252.40M | 252.32M | 252.13M | 250.91M | 250.30M | 251.90M | 251.10M | 250.88M | 250.00M | 250.00M |
Source: https://incomestatements.info
Category: Stock Reports